Outset Medical, Inc. OM R2K
Healthcare · Medical Devices · United States
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
READ MORE ›$4.89
-72.17% 1Y
Market & Price
Market Cap
$90.65M
Current Price
$4.89
High / Low (52W)
$21.24 / $3.16
Beta
1.91
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$6.99
Price to Book
0.70
P/S
0.77
EV/EBITDA
-0.56
Dividend Yield
-
Profitability & Returns
ROCE
-29.53%
ROE
-53.17%
ROA
-15.26%
Profit Margin
-63.65%
Op Margin
-60.72%
EPS (Latest Qtr)
$-1.03
EPS (TTM)
$-2.74
Balance Sheet & Liquidity
Debt/Equity
0.91
Quick Ratio
4.84
Current Ratio
6.29
Debt
$101.61M
Total Assets
$264.50M
Current Assets
$250.88M
Working Capital
$213.25M
Ownership
Promoter Holding
3.58%
Chg in Prom Hold
-
FII / Inst Holding
84.16%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$35.56M
Total Revenue (TTM)
$117.59M
EBITDA
$-63.39M
Free Cash Flow
$-10.46M
Operating Cash Flow
$-33.51M
Shares Outstanding
18.54M
Gross Margin
40.64%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
1.17%
Profit 5Y
16.63%
Revenue (YoY)
-6.30%
Earnings (YoY)
-
PROS
- Profit CAGR of 16.6% over 5 years.
CONS
- Trading 77.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OM Outset Medical, Inc. R2K | 4.89 | - | $90.65M | - | -29.53% | -53.17% | 1.17% | 16.63% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.49M | 2.87M | 2.63M | 7.08M | 7.19M | 11.74M | 13.76M | 17.25M | 22.92M | 25.22M | 26.32M | 30.55M | 25.06M | 27.76M | 33.47M | 36.04M | 30.36M | 28.17M | 27.39M | 28.67M | 29.75M | 31.42M | 29.43M | 28.87M | 27.86M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.69M | 19.55M | 17.84M | 16.64M | 15.77M |
| Gross Profit | -5.26M | -4.47M | -5.29M | -2.78M | -3.56M | -4.76M | -5.13M | 417.00K | 289.00K | 1.05M | 2.95M | 4.44M | 3.78M | 4.34M | 6.43M | 7.70M | 7.16M | 8.21M | 9.78M | 9.82M | 11.07M | 11.87M | 11.59M | 12.23M | 12.10M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 27.46M | 28.73M | 27.40M | 29.86M | 29.01M |
| Operating Income | - | - | -18.45M | - | -20.21M | -24.91M | -40.73M | - | -29.68M | -29.91M | -30.14M | -36.48M | -43.72M | -41.00M | -43.48M | -43.48M | -45.45M | -36.91M | -30.76M | -23.84M | -16.40M | -16.86M | -15.81M | -17.63M | -16.92M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -20.81M | -13.81M | -12.95M | -15.07M | -14.60M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.56M | 3.48M | 3.48M | 3.44M | 3.37M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -25.67M | -18.44M | -17.43M | -19.40M | -18.76M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 115.00K | 104.00K | 404.00K | 95.00K | 217.00K |
| Net Income | -16.42M | -17.03M | -15.40M | -19.45M | -20.65M | -26.50M | -42.29M | -32.04M | -30.02M | -30.21M | -30.47M | -36.89M | -43.84M | -40.78M | -43.97M | -44.05M | -46.18M | -39.94M | -34.45M | -27.94M | -25.78M | -18.54M | -17.84M | -19.49M | -18.98M |
| Diluted EPS | - | - | - | - | 0.74 | -4.58 | -3.44 | -0.75 | -0.70 | -0.66 | -0.65 | -0.78 | -0.92 | -0.85 | -0.90 | -0.90 | -0.93 | -11.77 | -9.96 | -8.02 | -3.66 | -1.04 | -1.00 | -1.09 | -1.03 |
| R&D Expense | - | - | 5.71M | - | 5.84M | 6.05M | 9.18M | - | 7.57M | 8.03M | 9.73M | 10.83M | 13.52M | 13.06M | 13.79M | 14.91M | 16.08M | 12.63M | 9.73M | 8.14M | 5.51M | 5.29M | 5.38M | - | 5.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.01M | 15.08M | 49.94M | - | 115.38M | 130.38M | 113.69M | 119.48M |
| Cost of Revenue | - | - | - | - | 97.54M | 101.38M | 75.12M | 72.72M |
| Gross Profit | -6.12M | -17.80M | -13.04M | - | 17.83M | 29.00M | 38.56M | 46.75M |
| Operating Expenses | - | - | - | - | 178.85M | 198.77M | 151.94M | 113.46M |
| Operating Income | -46.56M | -70.31M | -117.47M | - | -161.02M | -169.77M | -113.38M | -66.71M |
| EBITDA | - | - | - | - | -153.93M | -153.79M | -97.89M | -62.64M |
| Interest Expense | - | - | - | - | 3.57M | 12.68M | 23.87M | 13.95M |
| Pretax Income | - | - | - | - | -162.66M | -172.27M | -127.48M | -80.94M |
| Tax Provision | - | - | - | - | 295.00K | 523.00K | 491.00K | 718.00K |
| Net Income | -49.78M | -68.30M | -121.49M | - | -162.96M | -172.80M | -127.98M | -81.65M |
| Diluted EPS | - | - | -4.85 | - | -50.70 | -52.20 | -36.90 | -5.37 |
| R&D Expense | 22.92M | 23.33M | 28.85M | 36.74M | 48.85M | 57.31M | 38.40M | 21.23M |
Compounded Sales Growth
| 5 Years: | 1.17% |
| 1 Year: | -6.30% |
Compounded Profit Growth
| 5 Years: | 16.63% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -72.17% |
| 6 Months: | +9.40% |
| 3 Months: | +40.11% |
| 1 Month: | +16.99% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 88.37M | 403.83M | - | 400.12M | 313.80M | 275.80M | 264.50M |
| Current Assets | - | - | - | - | - | 373.64M | 291.22M | 258.22M | 250.88M |
| Cash & Equivalents | - | - | 36.93M | 294.97M | - | 73.22M | 68.51M | 124.01M | 35.01M |
| Inventory | - | - | - | - | - | 51.48M | 49.22M | 59.39M | 47.61M |
| Receivables | - | - | - | - | - | 28.07M | 32.98M | 35.62M | 28.33M |
| Total Liabilities | - | - | 51.11M | 75.22M | - | 154.12M | 190.91M | 248.98M | 137.54M |
| Current Liabilities | - | - | 24.91M | 36.69M | - | 51.95M | 55.32M | 45.38M | 37.63M |
| Long Term Debt | - | - | 21.56M | 29.67M | - | 96.34M | 130.11M | 197.38M | 96.24M |
| Total Debt | - | - | - | - | - | 103.23M | 136.19M | 201.86M | 101.25M |
| Total Equity | -215.94M | -287.95M | -372.19M | 328.61M | - | 245.99M | 122.89M | 26.82M | 126.95M |
| Shares Outstanding | - | - | - | - | - | 3.23M | 3.35M | 3.53M | 18.17M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -46.44M | -70.29M | -99.02M | - | -145.73M | -131.37M | -116.30M | -46.33M |
| Investing Cash Flow | -68.78M | 74.30M | 3.95M | - | -66.30M | 83.03M | 103.94M | -97.68M |
| Financing Cash Flow | 134.87M | 249.00K | 385.68M | - | 72.90M | 43.65M | 67.87M | 55.50M |
| Capital Expenditure | -1.77M | -3.29M | -9.08M | - | -8.32M | -3.44M | -912.00K | -798.00K |
| Free Cash Flow | -48.21M | -73.58M | -108.09M | - | -154.05M | -134.81M | -117.22M | -47.12M |
| Net Change in Cash | - | - | - | - | -139.13M | -4.70M | 55.51M | -88.51M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -304.7% | -118.1% | -26.1% | - | 15.5% | 22.2% | 33.9% | 39.1% |
| Operating Margin % | -2,320.0% | -466.3% | -235.2% | - | -139.6% | -130.2% | -99.7% | -55.8% |
| Net Margin % | -2,480.3% | -453.0% | -243.3% | - | -141.2% | -132.5% | -112.6% | -68.3% |
| ROE % | 17.3% | 18.4% | -37.0% | - | -66.2% | -140.6% | -477.2% | -64.3% |
| ROCE % | - | -110.8% | -32.0% | - | -46.2% | -65.7% | -49.2% | -29.4% |
Shareholding Pattern
Insiders
3.58%
Institutions
84.16%
Public Float
87.29%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.79% | 2.74M | $13.41M |
| 2 | BML Capital Management, LLC | 10.26% | 1.90M | $9.30M |
| 3 | Blackrock Inc. | 6.81% | 1.26M | $6.18M |
| 4 | Bank of America Corporation | 5.12% | 949.40K | $4.64M |
| 5 | Perceptive Advisors Llc | 4.50% | 833.33K | $4.07M |
| 6 | AQR Capital Management, LLC | 4.36% | 808.28K | $3.95M |
| 7 | Vanguard Capital Management LLC | 4.12% | 763.82K | $3.74M |
| 8 | Pfm Health Sciences, Lp | 3.21% | 594.63K | $2.91M |
| 9 | Ensign Peak Advisors, Inc | 2.84% | 526.59K | $2.58M |
| 10 | Assenagon Asset Management S.A. | 2.72% | 504.09K | $2.47M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OM
No recent headlines available.